ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2005
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood.The Cochrane database of systematic reviews · 2016Pooled it
- Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2011Guideline
- SEOM clinical guidelines for the treatment of antiemetic prophylaxis in cancer patients receiving chemotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2010Guideline
- Efficacy of palonosetron and ramosetron on postoperative nausea and vomiting related to intravenous patient-controlled analgesia with opioids after gynecological laparoscopic surgery (double-blinded prospective randomized controlled trial).Journal of anesthesia · 2015Trial
- Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Trial
- Trial
- Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012Trial
- Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.Journal of experimental & clinical cancer research : CR · 2009Trial
- Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2009Trial
- A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2007Trial
- Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2007Trial
- 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial.The Lancet. Oncology · 2005Trial
- The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy.Advanced biomedical research · 2023Article
- The Antiemetic Effect of Xiao-Ban-Xia-Tang Formula against Cisplatin-Induced Emesis is Mediated through Inhibition of NLRP3 Inflammasome Activation in a Rat Pica Model.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Cisplatin increases the number of enterochromaffin cells containing substance P in rat intestine.Naunyn-Schmiedeberg's archives of pharmacology · 2018Article
- A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.Therapeutics and clinical risk management · 2017Article
- A qualitative study investigating chemotherapy-induced nausea as a symptom cluster.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014Article
- Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014Article
- Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012Article
- Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol).Systematic reviews · 2012Review
Corrections and comments
- Erratum issuedDosage error in article text
Authors and funding
10 authors at 9 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper uses an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents. We address issues of dose, schedule, and route of administration of five selective 5-HT(3) antagonists. We conclude that for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration, even with chemotherapy of high emetic risk. Selective antagonists of the type 3 serotonin receptor (5-HT(3)) in combination with dexamethasone and aprepitant are the standard of care for the prevention of emesis following chemotherapy of high emetic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.